Goldman Sachs Group Inc. Has $1.46 Million Stake in Zevra Therapeutics, Inc. $ZVRA

Key Points

• Goldman Sachs Group Inc. has reduced its stake in Zevra Therapeutics by 22.1%, now owning 194,813 shares valued at approximately $1.46 million.
• Other institutional investors, including Rhumbline Advisers and Woodline Partners, have increased their holdings in Zevra Therapeutics during the same quarter, indicating continued interest among institutional players.
• Wall Street analysts have mixed opinions on ZVRA, with Cantor Fitzgerald raising its price target to $29.00, while Zacks Research downgraded it to a "hold," reflecting varying confidence in the company's future performance.

Goldman Sachs Group Inc. reduced its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 22.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 194,813 shares of the company's stock after selling 55,122 shares during the period. Goldman Sachs Group Inc. owned approximately 0.36% of Zevra Therapeutics worth $1,459,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Woodline Partners LP boosted its stake in shares of Zevra Therapeutics by 11.5% in the first quarter. Woodline Partners LP now owns 4,615,625 shares of the company's stock valued at $34,571,000 after buying an additional 476,032 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of Zevra Therapeutics in the fourth quarter valued at approximately $53,000. Millennium Management LLC boosted its stake in shares of Zevra Therapeutics by 138.2% in the fourth quarter. Millennium Management LLC now owns 233,132 shares of the company's stock valued at $1,944,000 after buying an additional 135,246 shares during the period. Deutsche Bank AG boosted its stake in shares of Zevra Therapeutics by 25.4% in the fourth quarter. Deutsche Bank AG now owns 50,906 shares of the company's stock valued at $425,000 after buying an additional 10,306 shares during the period. Finally, ProShare Advisors LLC bought a new stake in shares of Zevra Therapeutics in the fourth quarter valued at approximately $145,000. 35.03% of the stock is currently owned by institutional investors.

Insider Activity at Zevra Therapeutics

In other news, Director John B. Bode purchased 5,000 shares of the company's stock in a transaction dated Tuesday, August 19th. The stock was bought at an average cost of $9.16 per share, for a total transaction of $45,800.00. Following the purchase, the director owned 45,000 shares of the company's stock, valued at approximately $412,200. The trade was a 12.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.40% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ZVRA. Wall Street Zen cut Zevra Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, September 13th. Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, August 13th. Zacks Research cut Zevra Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, August 18th. Cantor Fitzgerald upped their target price on Zevra Therapeutics from $25.00 to $29.00 and gave the stock an "overweight" rating in a research note on Thursday, July 10th. Finally, HC Wainwright initiated coverage on Zevra Therapeutics in a research note on Wednesday, July 2nd. They set a "buy" rating and a $26.00 target price for the company. Eight research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $23.71.

Zevra Therapeutics Price Performance

Shares of ZVRA traded up $0.26 during trading hours on Tuesday, reaching $8.21. The stock had a trading volume of 1,372,676 shares, compared to its average volume of 831,842. Zevra Therapeutics, Inc. has a 12 month low of $6.19 and a 12 month high of $13.16. The stock has a market capitalization of $460.55 million, a PE ratio of -38.91 and a beta of 1.56. The company has a debt-to-equity ratio of 0.52, a quick ratio of 7.81 and a current ratio of 7.85. The company's 50-day moving average is $9.91 and its two-hundred day moving average is $8.91.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.